Press release
Atrial Fibrillation Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight
Stay ahead in understanding the Atrial Fibrillation Treatment Landscape @ https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Atrial Fibrillation Pipeline Report
* On June 05, 2026- Janssen Research & Development LLC initiated a phase 3 study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
* DelveInsight's Atrial Fibrillation pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Atrial Fibrillation treatment.
* The leading Atrial Fibrillation Companies such as HUYA Bioscience, InCarda Therapeutics, Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.
* Promising Atrial Fibrillation Pipeline Therapies such as Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
Stay informed about the cutting-edge advancements in Atrial Fibrillation Treatments @ Atrial Fibrillation Clinical Trials Assessment [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Atrial Fibrillation Overview
Atrial Fibrillation (AFib) is the most common type of arrhythmia, characterized by irregular and often rapid heartbeats. This condition arises from abnormal electrical impulses in the atria, the upper chambers of the heart, leading to ineffective atrial contractions. As a result, blood flow within the heart becomes turbulent, increasing the risk of clot formation, which can lead to stroke or other cardiovascular complications. AFib can be paroxysmal (occasional), persistent, or permanent, depending on its duration and response to treatment. Patients with AFib may experience a range of symptoms, from mild to severe.
Atrial Fibrillation Emerging Drugs Profile
* Etripamil: Milestone Pharmaceuticals Inc.
Etripamil is an investigational, fast-acting L-type calcium channel blocker delivered as a nasal spray, developed for on-demand, self-administered treatment of paroxysmal supraventricular tachycardia (PSVT). As Milestone's lead candidate, Etripamil is designed to offer rapid symptom relief outside of a clinical setting, potentially transforming the management of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR). It is currently in Phase III development for AFib-RVR.
* HBI-3000: HUYA Bioscience
HBI-3000 is a multi-ion channel blocker with in vitro inhibitory effects on INa-Peak, INa-Late, ICa, L and IKr being developed by HUYABIO International for the conversion of recent onset atrial fibrillation. The drug's preclinical and clinical pharmacology supports the potential of HBI-3000 to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing. Data from the first in human Phase I trial of the IV formulation were presented during a poster session at the American Heart Association 2019 annual meeting. Currently, the drug is in the Phase II stage of its development for the treatment of Atrial Fibrillation.
The Atrial Fibrillation Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
* Atrial Fibrillation Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.
Get a detailed analysis of the latest innovations in the Atrial Fibrillation pipeline @ Atrial Fibrillation Unmet Needs [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Atrial Fibrillation Companies
HUYA Bioscience, InCarda Therapeutics, Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.
Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Atrial Fibrillation Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Atrial Fibrillation Treatment by visiting our website @ Atrial Fibrillation Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Atrial Fibrillation Pipeline Report
* Coverage- Global
* Atrial Fibrillation Companies- HUYA Bioscience, InCarda Therapeutics, Inc., Milestone Pharmaceuticals, Verseon, Thryv Therapeutics Inc., Vivasc Therapeutics and others.
* Atrial Fibrillation Pipeline Therapies- Anticoagulant Oral, SB424323, Dapagliflozin, Etripamil, Dronedarone, Milvexian, Apixaban, OMT-28 and others.
* Atrial Fibrillation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Atrial Fibrillation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Read the full details of Atrial Fibrillation Pipeline on our website @ Atrial Fibrillation Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Atrial Fibrillation: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Atrial Fibrillation- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Etripamil: Milestone Pharmaceuticals Inc.
* Mid Stage Products (Phase II)
* Early Stage Products (Phase I)
* HBI-3000: HUYA Bioscience
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Atrial Fibrillation Key Companies
* Atrial Fibrillation Key Products
* Atrial Fibrillation- Unmet Needs
* Atrial Fibrillation- Market Drivers and Barriers
* Atrial Fibrillation- Future Perspectives and Conclusion
* Atrial Fibrillation Analyst Views
* Atrial Fibrillation Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atrial-fibrillation-pipeline-shows-potential-with-active-contributions-from-10-key-companies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atrial Fibrillation Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight here
News-ID: 4542778 • Views: …
More Releases from ABNewswire
Liquid Biopsy Market is Expected to Witness Robust Growth by 2032, Estimates Del …
Liquid biopsy companies such as Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health, Personal Genome Diagnostics, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., and others are driving innovation and growth in the global liquid biopsy market.
DelveInsight's "Liquid Biopsy - Market…
Lupus Nephritis Pipeline Accelerates as 35+ Pharma Companies Rigorously Develop …
DelveInsight's "Lupus Nephritis Pipeline Insight 2026" report provides comprehensive insights about 35+ companies and 42+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Niemann-Pick Type Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pion …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's…
Allergic Rhinitis Market Size Expected to Witness Significant Growth by 2034, es …
Emerging therapies including REGN5713-5714-5715 (Regeneron Pharmaceuticals), Grass MATA MPL (Allergy Therapeutics), and improved formulations of established treatments are driving market expansion and providing new therapeutic options for allergic rhinitis patients.
DelveInsight's "Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Allergic Rhinitis, historical and forecasted epidemiology, as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United…
More Releases for Atrial
Rising Cardiovascular Disease Rates Drive Growth In Atrial Flutter: A Key Driver …
The Atrial Flutter Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Atrial Flutter Market Size and Its Estimated Growth Rate?
In recent times, the market size for atrial flutter has seen swift growth. The market evaluation is expected to rise from $19.92…
Elevated Prevalence Of Atrial Fibrillation Fuels Growth In The Left Atrial Appen …
What Are the Projected Growth and Market Size Trends for the Left Atrial Appendage Closure Device Market?
The left atrial appendage closure device market will grow from $1.67 billion in 2024 to $2 billion in 2025, at a CAGR of 19.5%. The growth is attributed to the rising prevalence of atrial fibrillation, advancements in stroke prevention strategies, clinical evidence and research, minimally invasive alternatives, and a preference for non-pharmacological options.
The left…
Atrial Fibrillation Surgery Devices Market - Restoring Rhythm, Transforming Live …
Newark, New Castle, USA: The "Atrial Fibrillation Surgery Devices Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Atrial Fibrillation Surgery Devices Market: https://www.growthplusreports.com/report/atrial-fibrillation-surgery-devices-market/8777
This latest report researches the…
Atrial Fibrillation Market - Unveiling the Path to a Steady Heart: Advancements …
Newark, New Castle, USA - new report, titled Atrial Fibrillation Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Atrial Fibrillation market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Atrial Fibrillation market. The report offers an overview of the market, which…
Atrial Fibrillation Market Insights, Forecast to 2030
The report extensively examines the global Atrial Fibrillation market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Atrial Fibrillation . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to…
